EGFR and chronic liver failure: Further study revealed that the EGFR–ERK–Sox9 axis suppresses LPC-to-hepatocyte differentiation in zebrafish, indicating EGFR inhibitors as a proregenerative therapeutic drug for patients with ESLD [29].